CS
AIMT

Candriam SCA’s Aimmune Therapeutics AIMT Stock Holding History

Candriam SCA’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-262,804
Closed -$9.05M – 868
2020
Q3 		$9.05M Buy
+262,804
New +$5.6M 0.09% 256

Candriam SCA's AIMT Position: Q4 2020 in Review

Candriam SCA sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 262,804 shares — an estimated $9.05M sold.

Candriam SCA first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $9.05M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Candriam SCA reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Candriam SCA sold 262,804 Aimmune Therapeutics shares in Q4 2020, an estimated $9.05M.
  • Candriam SCA first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Candriam SCA's Aimmune Therapeutics position peaked at $9.05M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Candriam SCA's 13F filing for Q4 2020, filed 22 Jan 2021.